Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Adaptimmune Therapeutics Plc
473ACurrent price
0.8 EUR
+0.055 EUR (+7.38%)
Last closed
0.77 USD
Company
www.adaptimmune.com
ISIN
US00653A1079
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
203 803 184 USD
Yield for 12 month
+18.24 %
1Y
3Y
5Y
10Y
15Y
473A
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.56 USDP/E ratio
–Dividend Yield
–Current Year
+60 514 653 USD
Last Year
+27 148 000 USD
Current Quarter
+128 374 752 USD
Last Quarter
+5 678 000 USD
Current Year
+50 657 594 USD
Last Year
-100 578 000 USD
Current Quarter
+125 629 679 USD
Last Quarter
+2 849 616 USD
Key Figures 473A
1 year
3 years
5 years
10 years
EBITDA
-72 880 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-15.84 %
PEG Ratio
0.11
Return On Equity TTM
-65.04 %
Wall Street Target Price
2.56 USD
Revenue TTM
141 459 008 USD
Book Value
0.38 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
2399.6 %
Dividend Yield
–
Gross Profit TTM
-100 578 000 USD
Earnings per share
-0.36 USD
Diluted Eps TTM
-0.36 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-51.25 %
Dividend Analytics 473A
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 473A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
30.03.2018
Stock Valuation 473A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.2571
Price Sales TTM
1.4407
Enterprise Value EBITDA
-1.7076
Price Book MRQ
2.1169
Financials 473A
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 473A
For 52 weeks
0.42 USD
2.05 USD
50 Day MA
0.92 USD
Shares Short Prior Month
6 086 908
200 Day MA
1.13 USD
Short Ratio
5
Shares Short
5 555 099
Short Percent
3.26 %
BeatStart